Impact of RAS-MAPK Pathway Genetic Alterations on Radiotherapy Response in Metastatic Lung Adenocarcinoma
Driver alterations in the <i>RAS-MAPK</i> signaling pathway confer radioresistance in metastatic NSCLC. These genetic alterations may serve as biomarkers to personalize RT strategies or as targets to enhance radiosensitivity.
Authors
- Eric Lis (ORCID: https://orcid.org/0000-0002-4138-3867)
- Adam M. Schmitt (ORCID: https://orcid.org/0000-0002-7723-0651)
- G. Cederquist (ORCID: https://orcid.org/0000-0003-4749-6093)
- Erik S. Anderson (ORCID: https://orcid.org/0000-0001-5014-8706)
- Lillian A. Boe (ORCID: https://orcid.org/0000-0001-6279-9987)
- Ori Barzilai (ORCID: https://orcid.org/0000-0002-4037-8716)
- Daniel S. Higginson (ORCID: https://orcid.org/0000-0002-6686-7454)
- Mark H. Bilsky (ORCID: https://orcid.org/0000-0001-6091-0709)
- Yoshiya Yamada (ORCID: https://orcid.org/0000-0003-1212-2331)
- William Newman (ORCID: https://orcid.org/0000-0003-1775-037X)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1200/po-25-00082
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00